Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database. [PDF]
Front PharmacolGianguzzo VM +11 more
europepmc +1 more source
Current status of the development of dengue vaccines. [PDF]
Vaccine XLee MF, Long CM, Poh CL.
europepmc +1 more source
Advancements in dengue vaccines: A historical overview and pro-spects for following next-generation candidates. [PDF]
J MicrobiolYan K, Mao L, Lan J, Xiao Z.
europepmc +1 more source
Dengue and dengue hemorrhagic fever : information for health care practitioners [PDF]
"Dengue is a mosquito-borne disease caused by any one of four closely related dengue viruses (DENV-1, -2, -3, and -4). Infection with one serotype of DENV provides immunity to that serotype for life, but provides no long-term immunity to other serotypes.
core
Prospects for dengue vaccines for travelers. [PDF]
Clin Exp Vaccine Res, 2016 Lim SK +4 more
europepmc +1 more source
Key Amino Acid Substitution for Infection-Enhancing Activity-Free Designer Dengue Vaccines. [PDF]
iScience, 2019 Yamanaka A, Konishi E.
europepmc +1 more source
Dengue Serostatus and Dengue Vaccine Safety and Efficacy
New England Journal of Medicine, 2018 Posfay-Barbe KM, L’Huillier AG
openaire +5 more sources
Dengue vaccines: closer but not there yet [PDF]
Memórias do Instituto Oswaldo Cruz, 2011 Galler, Ricardo +2 more
openaire +4 more sources
From vaccine availability to effective deployment: Closing the arboviral vaccine access gap. [PDF]
Hum Vaccin ImmunotherTee KK, Mu D, Wang B, Xia X.
europepmc +1 more source
Evaluating knowledge and attitudes towards dengue fever and its vaccination in China: A questionnaire-based study in healthcare practitioners. [PDF]
PLoS Negl Trop DisLam I, Yao Y, Sun Y, Xia Y, Lu Y.
europepmc +1 more source